Elizabeth Yeu Lin is Director at Tarsus Pharmaceuticals, Inc. (TARS). They have made 6 open-market trades across 2 companies since 2022, most recently 2026-09-04.
CIK 0001842190
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
3 open-market purchases totalling $1.0M since 2022, against 3 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| STAA | 5,099 | $108K |
| TARS | 1,590 | $108K |
| Total | $217K |
Shares reported on the most recent Form 4, priced at the 2026-09-09 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| TARS | SELL · 10b5-1 | 2026-09-04 | 2026-09-09 | $87.50 | $1.2M | -5.4% | -10.7% | — |
| TARS | SELL · 10b5-1 | 2026-09-01 | 2026-09-03 | $77.56 | $898K | -6.1% | -10.0% | — |
| TARS | SELL | 2026-03-17 | 2026-03-19 | $68.36 | $78K | +5.1% | -1.2% | -6.4% |
| TARS | SELL | 2025-12-16 | 2025-12-17 | $79.50 | $165K | +5.2% | -9.1% | -10.8% |
| TARS | SELL | 2025-06-16 | 2025-06-17 | $41.08 | $41K | +2.1% | +4.3% | +25.0% |
| STAA | BUY | 2023-09-21 | 2023-09-22 | $40.00 | $100K | -1.7% | +5.4% | -18.3% |
| TARS | BUY | 2023-08-15 | 2023-08-17 | $16.80 | $319K | +4.8% | -0.4% | +7.9% |
| TARS | BUY | 2022-09-14 | 2022-09-16 | $16.12 | $593K | +19.2% | +16.7% | -1.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.